Natural history of addiction in psychotic heroin-addicted patients at their first agonist opioid treatment

Addictive Disorders and their Treatment

Volumn 12, Issue 1, 2013, Pages 31-39

  Maremmani, Angelo Giovanni Icro ^a,b   Bacciardi, Silvia ^a   Rovai, Luca ^a   Rugani, Fabio ^a   Dell'Osso, Liliana ^a   Maremmani, Icro ^a,b,c  

^a UNIVERSITY OF PISA   (Italy)

^b G DE LISIO INSTITUTE OF BEHAVIOURAL SCIENCES   (Italy)

^c AU CNS   (Italy)

Author keywords

natural history of addiction; opioids' antipsychotic effects; substance abuse related psychosis

Indexed keywords

AMPHETAMINE; BENZODIAZEPINE; CANNABINOID; COCAINE; HYPNOTIC AGENT; METHADONE; MORPHINE; OPIATE; PSYCHEDELIC AGENT;

ADULT; ANAMNESIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HEROIN DEPENDENCE; HUMAN; LEISURE; MALE; MENTAL HEALTH; OCCUPATION; PRIORITY JOURNAL; PSYCHOSIS; SEXUAL DYSFUNCTION; SOCIALIZATION; SUBSTANCE ABUSE;

EID: 84874425394     PISSN: 15315754     EISSN: None     Source Type: Journal    
DOI: 10.1097/ADT.0b013e31824c5d1b     Document Type: Article

References (74)

1. von Limbeek J, Wouters L, Kaplan CD, et al. Prevalence of psychopathology in drug-addicted Dutch. J Subst Abuse Treat. 1992;9:43-52.
2. Hall W, Degenhardt L. Cannabis and the increased incidence and persistence of psychosis. BMJ. 2011; 342:d719.
3. Kuepper R, Morrison PD, van Os J, et al. Does dopamine mediate the psychosis-inducing effects of cannabis? A review and integration of findings across disciplines. Schizophr Res. 2010;121:107-117.
4. Loga S, Loga-Zec S, Spremo M. Cannabis and psychiatric disorders. Psychiatr Danub. 2010;22:296-297.
5. Srisurapanont M, Arunpongpaisal S, Wada K, et al. Comparisons of methamphetamine psychotic and schizophrenic symptoms: a differential item functioning analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2011.
6. Karila L, Petit A, Cottencin O, et al. Methamphetamine dependence: consequences and complications. Presse Med. 2010;39:1246-1253.
7. Schep LJ, Slaughter RJ, Beasley DM. The clinical toxicology of metamfetamine. Clin Toxicol (Phila). 2010;48:675-694.
8. Floyd AG, Boutros NN, Struve FA, et al. Risk factors for experiencing psychosis during cocaine use: a preliminary report. J Psychiatr Res. 2006;40:178-182. (Pubitemid 43172880)
9. Carls KA, Ruehter VL. An evaluation of phencyclidine (PCP) psychosis: a retrospective analysis at a state facility. Am J Drug Alcohol Abuse. 2006;32:673-678. (Pubitemid 44871006)
10. Smith MJ, Thirthalli J, Abdallah AB, et al. Prevalence of psychotic symptoms in substance users: a comparison across substances. Compr Psychiatry. 2009;50:245-250.
11. Maremmani I, Lazzeri A, Pacini M, et al. Diagnostic and symptomatological features in chronic psychotic patients according to cannabis use status. J Psychoactive Drugs. 2004;36:235-241. (Pubitemid 39045760)
12. Extein I, Pottash ALC, Gold MS. A possible opioid receptor dysfunction in some depressive disorders. Ann N Y Acad Sci. 1982;398:113-119. (Pubitemid 13026040)
13. Pomara N, Sidtis JJ. Brain neurotoxic amyloid-beta peptides: their potential role in the pathophysiology of depression and as molecular therapeutic targets. Br J Pharmacol. 2010;161:768-770.
14. Tenore PL. Psychotherapeutic benefits of opioid agonist therapy. J Addict Dis. 2008;27:49-65.
15. Emrich HM. Endorphins in psychiatry. Psychiatr Dev. 1984;2:97-114.
16. Stoll AL, Rueter S. Treatment augmentation with opiates in severe and refractory major depression. Am J Psychiatry. 1999;156:2017.
17. Zis AP, Garland JE. Opioid peptides and depression: the neuroendocrine approach. Baillieres Clin Endocrinol Metab. 1991;5:97-117.
18. Bodkin JA, Zornberg GL, Lukas SE, et al. Buprenorphine treatment of refractory depression. J Clin Psychopharmacol. 1995;15:49-57.
19. Callaway E. Buprenorphine for depression: the un-adoptable orphan. Biol Psychiatry. 1996;39: 989-990. (Pubitemid 26191346)
20. Grimwood S, Lu Y, Schmidt AW, et al. Pharmacological characterization of 2-methyl-N-((20-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for kappa opioid receptors. J Pharmacol Exp Ther. 2011.
21. Berrocoso E, Sanchez-Blazquez P, Garzon J, et al. Opiates as antidepressants. Curr Pharm Des. 2009; 15:1612-1622.
22. Gerner RH, Catlin DH, Gorelick DA, et al. Betaendorphin. Intravenous infusion causes behavioral change in psychiatric inpatients. Arch Gen Psychiatry. 1980;37:642-647. (Pubitemid 10123996)
23. Woolf CJ, Hashmi M. Use and abuse of opioid analgesics: potential methods to prevent and deter non-medical consumption of prescription opioids. Curr Opin Investig Drugs. 2004;5:61-66. (Pubitemid 38559326)
24. Varga E, Sugerman AA, Apter J. The effect of codeine on involutional and senile depression. Ann NY Acad Sci. 1982;398:103-105. (Pubitemid 13026038)
25. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alchool and other drug abuse. JAMA. 1990;19:2511-2518.
26. Maremmani I, Canoniero S, Pacini M. Methadone dose and retention in treatment of heroin addicts with bipolar I disorder comorbidity. Preliminary results. Heroin Addict Relat Clin Probl. 2000;2: 39-46.
27. Gold MS, Pottash ALC, Sweeney DR, et al. Antimanic, antidepressant, and antipanic effects of opiate: clinical, neuro-anatomical, and biochemical evidence. Ann N Y Acad Sci. 1982;398:140-150. (Pubitemid 13026043)
28. Pani PP, Agus A, Gessa GL. Methadone as a mood stabilizer [Letter]. Heroin Addict Relat Clin Probl. 1999;1:43-44.
29. Maremmani I, Pacini M, Pani PP. Effectiveness of buprenorphine in double diagnosed patients. Buprenorphine as psychothropic drug. Heroin Addict Relat Clin Probl. 2006;8:31-48.
30. Maremmani I, Pacini M, Lovrecic M, et al. Maintenance therapy with opioid agonist for heroin addicted patients. Usefulness in the treatment of comorbid psychiatric diseases. In: Waal H, Haga E, eds. Maintenance Treatment of Heroin Addiction. Evidence at the Crossroads. Oslo: Cappelen Akademisk Forlag. 2003;221-233.
31. Maremmani I, Pacini M, Lovrecic M. Clinical foundations for the use of methadone in jail. Heroin Addict Relat Clin Probl. 2004;6:53-72.
32. Maremmani I, Marini G, Fornai F. Naltrexone-induced panic attacks. Am J Psychiatry. 1998;155:447.
33. Maremmani I, Marini G, Castrogiovanni P, et al. The effectiveness of the combination fluoxetine-naltrexone in bulimia nervosa. Eur Psychiatry. 1996;11: 322-324. (Pubitemid 26354553)
34. Volovka SJ, Anderson B, Koz G. Naloxone and naltrexone in mental illness and tardive dyskinesia. Ann N Y Acad Sci. 1982;398:143-152.
35. BellM. Morphine and morphinomania. N Y State Med J. 1911;93:680-682.
36. Schwartz JM, Ksir C, Koob GF, et al. Changes in locomotor response to beta-endorphin microinfusion during and after opiate abstinence syndrome-a proposal for a model of the onset of mania. Psychiatry Res. 1982;7:153-161. (Pubitemid 13240632)
37. Pfeffer AZ, Ruble DC. Chronic psychoses and addiction to morphine. Arch Neurol Psychiatry. 1946; 56:655-672.
38. Gerard DL, Kornetsky C. Adolescent opiate addiction: a study of control and addict sujects. Psychoanal Q. 1955;19:457-486.
39. Shoval G, Zalsman G, Nahshoni E, et al. The use of illicit substances in adolescent schizophrenia inpatients. Int J Adolesc Med Health. 2006;18: 643-648. (Pubitemid 46290861)
40. Maremmani AGI, Dell'Osso L, Pacini M, et al. Dual diagnosis and chronology of illness in 1090 treatment seeking Italian heroin dependent patients. J Addict Dis. 2011;30:123-135.
41. Berger PA, Watson SJ, Akil H, et al. Betaendorphin and schizophrenia. Arch Gen Psychiatry. 1980;37: 635-640.
42. Feinberg DT, Hartman N. Methadone and schizophrenia. Am J Psychiatry. 1991;148:1750-1751.
43. Levinson I, Rosenthal RN. Methadone withdrawal psychosis. J Clin Psychiatry. 1995;56:73-76.
44. Khantzian EJ. An ego/self theory of substance dependence: a contemporary psychoanalitic perspective. Nida Res Monogr. 1980;30:184-191.
45. McKenna GJ. The use of methadone as a psychotropic agent. Nat Conf Methadone Treat Proc. 1973;5:1317-1324.
46. Mueser KT, Yarnold PR, Levinson DF, et al. Prevalence of substance abuse in schizophrenia: demographic and clinical correlates. Schizophr Bull. 1990;16:31-56. (Pubitemid 20110374)
47. Resnick RB, Fink M, Freedmann AM. A cyclazocine typology in opiate dependence. Am J Psychiatry. 1970;126:1256-1260.
48. Resnick RB, Schuyten-Resnick E, Washton A. Narchotic antagonists in the treatment of opioid dependence: review and commentary. Compr Psychiatry. 1979;20:116-125.
49. Krausz M, Degkwitz P, Haasen C, et al. Opioid addiction and suicidality. Crisis. 1996;17:175-181.
50. Spensley J. Doxepin: a useful adjunct in the treatment of heroin addicts in amethadone program. Int J Addict. 1976;11:191-197.
51. Clouet DH. A biochemical and neurophysiological comparison of opioids and antipsychotics. Ann N Y Acad Sci. 1982;398:130-139. (Pubitemid 13026042)
52. PaciniM,Maremmani I. Methadone reduces the need for antipsychotic and antimanic agents in heroin addicts hospitalized for manic and/or acute psychotic episodes. Heroin Addict Relat Clin Probl. 2005;7: 43-48. (Pubitemid 43074767)
53. Gold MS, Redmond DE, Donabedian RK, et al. Increase in serum prolactin by exogenous and endogenous opiates: evidence for antidopamine and antipsychotic effects. Am J Psychiatry. 1978;135: 1415-1416. (Pubitemid 9060017)
54. Maremmani AGI, Rovai L, Pani PP, et al. Do methadone and buprenorphine have the same impact on psychopathological symptoms of heroin addicts? Ann Gen Psychiatry. 2011;10:17.
55. Maremmani I, Pani PP, Pacini M, et al. Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients. J Subst Abuse Treat. 2007;33:91-98. (Pubitemid 350198612)
56. Maremmani I, Pacini M, Pani PP, et al. The mental status of 1090 heroin addicts at entry into treatment: should depression be considered a "dual diagnosis"? Ann Gen Psychiatry. 2007;6:31.
57. Maremmani I, Pani PP, Pacini M, et al. Subtyping patients with heroin addiction at treatment entry: factors derived fron the SCL-90. Ann Gen Psychiatry. 2010;9:15.
58. Maremmani I, Castrogiovanni P. DAH-RS: Drug Addiction History Rating Scale. Pisa: University Press; 1989.
59. Lahmeyer HW, Channon RA, Schlemmer FJ. Psychoactive substance abuse. In: Flaherty JA, et al, ed. Psychiatry. Diagnosis & Therapy. San Mateo, CA: Appleton & Lange. 1988;182-199.
60. Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry. 2005;162:1403-1413. (Pubitemid 41105554)
61. Maremmani I, Popovic D. Heroin dependence. In: Maremmani I, ed. The Principles and Practice of Methadone Treatment. Pisa: Pacini Editore Medicina. 2009;21-30.
62. APA. DSM-IV-TR. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psichiatric Association; 2000.
63. Gold MS, Pottash AC, Sweeney DR, et al. Rapid opiate detoxification: clinical evidence of antidepressant and antpanic effects of opiates. Am J Psychiatry. 1979;982-983. (Pubitemid 9201228)
64. McKenna GJ. Methadone and opiate drugs: psychotropic effects and self medication. Ann N Y Acad Sci. 1982;398:44-55. (Pubitemid 13026031)
65. Maremmani I, Zolesi O, Agueci T, et al. Methadone doses and psychopathological symptoms during methadone maintenance. J Psychoactive Drugs. 1993;25:253-256. (Pubitemid 23298781)
66. Pani PP, Maremmani I, Pacini M, et al. Effect of psychiatric severity on the outcome of methadone maintenance treatment. Eur Addict Res. 2011;17: 80-89.
67. Maremmani I, Zolesi O, Aglietti M, et al. Methadone dose and retention during treatment of heroin addicts with Axis I psychiatric comorbidity. J Addict Dis. 2000;19:29-41. (Pubitemid 30659340)
68. Maremmani I, Pacini M, Lubrano S, et al. Long-term outcomes of treatment-resistant heroin addicts with and without DSM-IV axis I psychiatric comorbidity (dual diagnosis). Eur Addict Res. 2008;14:134-142. (Pubitemid 351841865)
69. Maremmani I, Pani PP, Popovic D, et al. Improvement of quality of life in heroin addicts: differences between methadone and buprenorphine treatment. Heroin Addict Relat Clin Probl. 2008;10:41-48.
70. Pani PP, Maremmani I, Pirastu R, et al. Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. Drug Alcohol Depend. 2000;60: 39-50. (Pubitemid 30255984)
71. Pani PP, Trogu E, Carboni G, et al. Psychiatric severity and treatment response in methadone maintenance treatment programmes: new evidence. Heroin Addict Relat Clin Probl. 2003;5:22-36.
72. Maremmani I, Pacini M, Pani PP, et al. Use of street methadone in italian heroin addicts presenting for opioid agonist treatment. J Addict Dis. 2009;28: 382-388.
73. Khantzian EJ. The self-medicatio hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry. 1985;142:1259-1264. (Pubitemid 16216560)
74. Maremmani I, Shinderman MS. Alcohol, benzodiazepines and other drugs use in heroin addicts treated with methadone. Polyabuse or undermedication? Heroin Addict Relat Clin Probl. 1999;1: 7-13.